2.

Phase III trials addressing the role of chemotherapy in the postoperative adjuvant therapy for early-stage CC with pathological risk factors

Author (ref.)	No. of eligible patients	FIGO stage	Histology	Study arms	Chemotherapy regimen	Survival
CC, cervival cancer; FIGO, International Federation of Gynecology and Obstetrics; 1, risk factors include pelvic lymph node metastasis and/or deep cervical invasion and/or tumor ≥4 cm and/or parametrial involvement and/or nonsquamous histology and/or positive surgical margins; 2, risk factors include pelvic lymph node metastases or parametrial involvement and/or vascular invasion; 3, risk factors include pelvic lymph node metastases and/or positive margins and/or parametrial involvement; 4, risk factors include vascular invasion and/or pelvic lymph node metastases and/or positive margins; SCC, squamous cell carcinoma; ADC, adeno-carcinoma; non-SCC, non-squamous cell carcinoma; ADS, adenosquamous carcinoma; CT, chemotherapy; RT, radiation therapy; NFT, no further therapy; CCRT, concomitant chemoradiotherapy; ACT, adjuvant chemotherapy; BLE, bleomycin; CDDP, cisplatin; CBDCA, carboplatin; PTX, paclitaxel; OS, overall survival; NS, not significant.
Curtin et al. (1996) (23)	89	IB–IIA1	SCC, ADC, Non-SCC	CT CT followed by RT and CT	BLE+CDDP	3-year OS 70% vs. 75% (NS)
Lahousen et al. (1999) (24)	76	IB–IIB2	SCC	CT RT NFT	BLE+CBDCA	5-year OS 86% vs. 80% vs. 81% (NS)
Peters et al. (2000) (25,26)	243	IA2–IIA3	SCC, ADC, ADS	RT CCRT+ACT	CDDP+5-FU (during RT and as ACT)	4-year OS 71% vs. 81% (P=0.007)
Sehouli et al. (2012) (27)	263	IB–IIB4	SCC, ADC, ADS	CCRT CT followed by RT	PTX+CBDCA	5-year OS 78.9% vs. 85.8% (P=0.25)